Carlos Errando-Smet1, Carlos Müller-Arteaga2, Marta Hernández3, Enrique Lenero4, Montse Roset5. 1. Department of Urology, Fundació Puigvert, Barcelona, Cartagena, Spain. 2. Department of Urology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. 3. Department of Medical Affairs, Astellas Pharma Europe B.V., Madrid, Spain. 4. Medical Affairs Global Development, Astellas Pharma, Northbrook, Illinois. 5. Health Economics and Outcomes Research, IMS Health, Barcelona, Spain.
Abstract
AIMS: To assess the relationship between storage-predominant LUTS and healthcare resource consumption and cost among males in Spain. METHODS: In this non-interventional, cross-sectional study, urologists enrolled males with storage-predominant LUTS and recorded the consumption of healthcare resources (medical visits, diagnostic tests/monitoring, treatment, and hospitalizations) within the previous 6 months. The cost of healthcare resources was calculated from unit costs extracted from a Spanish eHealth database. Severity of LUTS was assessed by the Bladder Self-Assessment Questionnaire (BSAQ) and patients were stratified by symptom score (<6 or ≥6) to assess the relationship between LUTS severity and healthcare resource consumption and cost. RESULTS: Among 610 enrolled patients (BSAQ symptom score <6, n = 191; BSAQ symptom score ≥6, n = 419), the majority (87.7%) consumed healthcare resources during the previous 6 months in the form of medical visits (86.2%), diagnostic tests/monitoring (83.4%), and treatment (85.9%). Patients with BSAQ symptom scores ≥6 used more healthcare resources compared with patients with BSAQ symptom scores <6. The most common treatments for LUTS were α-blockers used as monotherapy (n = 229 [37.5%]) or in combination with antimuscarinics (n = 227 [37.2%]). The estimated median annual cost was €1070 per patient, consisting of diagnostic tests/monitoring (54.6%), medical visits (20.5%), and treatment (29.6%), and was higher in patients with BSAQ symptom score ≥6 (€1127) than in patients with BSAQ symptom score <6 (€920; P < 0.001). CONCLUSIONS: More severe LUTS are associated with higher healthcare consumption and cost. These findings highlight the importance of symptom management in LUTS patients to help minimize healthcare consumption and cost.
AIMS: To assess the relationship between storage-predominant LUTS and healthcare resource consumption and cost among males in Spain. METHODS: In this non-interventional, cross-sectional study, urologists enrolled males with storage-predominant LUTS and recorded the consumption of healthcare resources (medical visits, diagnostic tests/monitoring, treatment, and hospitalizations) within the previous 6 months. The cost of healthcare resources was calculated from unit costs extracted from a Spanish eHealth database. Severity of LUTS was assessed by the Bladder Self-Assessment Questionnaire (BSAQ) and patients were stratified by symptom score (<6 or ≥6) to assess the relationship between LUTS severity and healthcare resource consumption and cost. RESULTS: Among 610 enrolled patients (BSAQ symptom score <6, n = 191; BSAQ symptom score ≥6, n = 419), the majority (87.7%) consumed healthcare resources during the previous 6 months in the form of medical visits (86.2%), diagnostic tests/monitoring (83.4%), and treatment (85.9%). Patients with BSAQ symptom scores ≥6 used more healthcare resources compared with patients with BSAQ symptom scores <6. The most common treatments for LUTS were α-blockers used as monotherapy (n = 229 [37.5%]) or in combination with antimuscarinics (n = 227 [37.2%]). The estimated median annual cost was €1070 per patient, consisting of diagnostic tests/monitoring (54.6%), medical visits (20.5%), and treatment (29.6%), and was higher in patients with BSAQ symptom score ≥6 (€1127) than in patients with BSAQ symptom score <6 (€920; P < 0.001). CONCLUSIONS: More severe LUTS are associated with higher healthcare consumption and cost. These findings highlight the importance of symptom management in LUTS patients to help minimize healthcare consumption and cost.
Authors: Mikołaj Przydacz; Marcin Chłosta; Łukasz Belch; Anna K Czech; Tomasz Wiatr; Katarzyna Gronostaj; Marek Lipinski; Piotr Chłosta Journal: Cent European J Urol Date: 2021-06-17
Authors: Tom Vredeveld; Esther van Benten; Rikie E P M Beekmans; M Patrick Koops; Johannes C F Ket; Jurgen Mollema; Stephan P J Ramaekers; Jan J M Pool; Michel W Coppieters; Annelies L Pool-Goudzwaard Journal: BMJ Open Date: 2022-04-29 Impact factor: 3.006
Authors: Margarita Landeira; Ana M Mora Blázquez; Rodrigo Martins de Almeida; Patrick J O Covernton; José Medina-Polo; Antonio Alcántara Montero Journal: Int J Clin Pract Date: 2020-09-19 Impact factor: 3.149